SAB Biotherapeutics, Inc.

SAB Biotherapeutics reported a net loss of $(22.5) million for the second quarter of 2026, an increase from $(10.1) million in the prior year period. Despite the higher net loss, diluted loss per share improved to $(0.28) from $(1.09) due to a significant increase in shares outstanding. The company successfully raised $88.7 million through a public offering in March 2026, which is expected to cover operating cash needs for at least the next twelve months and support ongoing clinical development, including the Phase 2b trial for SAB-142.

SAB Biotherapeutics reported a net loss of $22.5 million for Q2 2026, up from $10.1 million in Q2 2025. The company announced that enrollment for its registrational SAFEGUARD study is on track for completion in Q4 2026, with topline data expected in 2H 2027. Additionally, the PRISE-hATG study received a grant from Breakthrough T1D, and the company extended its operational runway through 2028.

SAB Biotherapeutics, Inc. announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., to support the PRISE-hATG clinical study. This study will evaluate SAB-142 in patients with Stage 3 Type 1 Diabetes (T1D) who are 100 days to two years from diagnosis, with SAB BIO co-funding the research. The PRISE-hATG study aims to assess if SAB-142 can preserve endogenous C-peptide and modulate immune responses, expanding the clinical evaluation of SAB-142 beyond earlier stages of the disease.

SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to support the PRISE-hATG clinical study, which SAB BIO will co-fund. This study will evaluate SAB-142, a fully human anti-thymocyte immunoglobulin (hATG), in patients with Stage 3 Type 1 Diabetes (T1D) who are 100 days to 2 years from diagnosis. The PRISE-hATG study aims to assess SAB-142's ability to preserve endogenous C-peptide and modulate immune responses, expanding the clinical evaluation of the drug beyond the earliest stages of the disease.

SAB Biotherapeutics announced it will present data on its lead program, SAB-142, at two major congresses in June 2026. An oral presentation at the American Diabetes Association's Scientific Sessions will cover clinical safety, pharmacokinetics, immunogenicity, and pharmacodynamics of repeat dosing. A poster presentation at the Federation of Clinical Immunology Societies Annual Meeting will detail the positive clinical translation of a juvenile NHP study for SAB-142. The company's Chief Medical Officer highlighted these forums as key opportunities to showcase SAB-142's profile and advance the registrational Phase 2b SAFEGUARD study, with topline data expected in the second half of 2027.

SAB Biotherapeutics reported a net loss of $(18.87) million for Q1 2026, a significant increase from $(5.20) million in Q1 2025. Despite this, basic and diluted loss per share improved to $(0.35) from $(0.56) due to a substantial increase in weighted-average common shares outstanding. The company bolstered its financial position through a March 2026 public offering, raising approximately $86.87 million in net proceeds, which increased cash and cash equivalents to $20.52 million and total stockholders' equity to $227.25 million.

SAB Biotherapeutics reported Q1 2026 financial results, including a net loss of $18.9 million, an increase from $5.2 million in Q1 2025. The company announced continued progress in its registrational SAFEGUARD trial for SAB-142, with enrollment on track for completion by end of 2026 and topline data expected in 2H 2027. Additional Phase 1 data for SAB-142 showed C-peptide preservation and improved glycemic control. A recent $95 million public offering bolstered its cash position to $217.6 million, providing an operational runway through 2028.

SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for the clinical and commercial manufacturing of its product, SAB-142. The agreement, effective April 28, 2026, has a term of five years post-FDA approval of SAB-142 and includes a minimum aggregate spend of $36 million following approval. Emergent will be the exclusive manufacturer, with provisions for SAB to establish an alternative source under limited conditions, securing a critical step for product commercialization.

SAB Biotherapeutics, Inc. announced its 2026 Virtual Annual Meeting of Stockholders will be held on June 18, 2026, at 10:00 AM ET. Stockholders of record as of April 20, 2026, are invited to vote on two key proposals: the election of four Class II directors and the ratification of EisnerAmper LLP as the independent auditor for fiscal year 2026. The Board recommends voting "FOR" both proposals.

SAB Biotherapeutics, Inc. announced the release of a presentation and a corresponding press release on April 22, 2026. These materials provide additional information regarding the company's Phase 1 clinical trial for SAB-142. The trial involves a human anti-thymocyte biologic, and the presentation is accessible via the company's investor relations website.